Total for the last 12 months
number of access : ?
number of downloads : ?
ID 117839
Saita, Kosuke The University of Tokyo
Sumitani, Masahiko The University of Tokyo
Nishizawa, Daisuke Tokyo Metropolitan Institute of Medical Science
Tamura, Takashi Nagoya University
Ikeda, Kazutaka Tokyo Metropolitan Institute of Medical Science
Wakai, Kenji Nagoya University
Sudo, Yoshika The University of Tokyo
Abe, Hiroaki The University of Tokyo
Otonari, Jun Kyushu University|International University of Health and Welfare
Ikezaki, Hiroaki Kyushu University
Takeuchi, Kenji Nagoya University
Hishida, Asahi Nagoya University
Tanaka, Keitaro Saga University
Shimanoe, Chisato Saga University
Takezaki, Toshiro Kagoshima University
Ibusuki, Rie Kagoshima University
Oze, Isao Aichi Cancer Center Research Institute
Ito, Hidemi Aichi Cancer Center Research Institute
Ozaki, Etsuko Kyoto Prefectural University of Medicine
Matsui, Daisuke Kyoto Prefectural University of Medicine
Nakamura, Yohko Chiba Cancer Center Research Institute
Kusakabe, Miho Chiba Cancer Center Research Institute
Suzuki, Sadao Nagoya City University
Nakagawa-Senda, Hiroko Nagoya City University
Kuriki, Kiyonori University of Shizuoka
Kita, Yoshikuni Tsuruga Nursing University
Nakamura, Yasuyuki Shiga University of Medical Science|Takeda Hospital
Momozawa, Yukihide RIKEN
Uchida, Kanji The University of Tokyo
cancer pain
genetic polymorphism
nonsteroidal anti-inflammatory drug usage
PTN gene
Content Type
Journal Article
Genetic factors play a role in individual differences in pain experience. Here, we performed a genome-wide association study (GWAS) to identify novel loci regulating pain processing. We conducted a 2-stage GWAS and the candidate single-nucleotide polymorphisms (SNPs) association study on pain experience using an exploratory cohort of patients with cancer pain. The confirmatory cohort comprised of participants from the general population with and without habitual use of analgesic medication. In the exploratory cohort, we evaluated pain intensity using a numerical rating scale, recorded daily opioid dosages, and calculated pain reduction rate. In the confirmatory cohort, pain experience was defined as habitual nonsteroidal anti-inflammatory drug usage. Using linear regression models, we identified candidate SNP in the exploratory samples, and tested the association between phenotype and experienced pain in the confirmatory samples. We found 1 novel SNP (rs11764598)—located on the gene encoding for pleiotrophin on chromosome 7—that passed the genome-wide suggestive significance at 20% false discovery rate (FDR) correction in the exploratory samples of patients with cancer pain (P = 1.31 × 10-7, FDR = 0.101). We confirmed its significant association with daily analgesic usage in the confirmatory cohort (P = .028), although the minor allele affected pain experience in an opposite manner. We identified a novel genetic variant associated with pain experience. Further studies are required to validate the role of pleiotrophin in pain processing.
Journal Title
Wolters Kluwer Health
Start Page
Published Date
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (, where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
Medical Sciences